Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
March 1, 2024BMJOpen Access

5PSQ-104 Real-world evidence: is ibrutinib as safe as evidence tells?

View Full Paper
Ask AI
Bookmark
Share

Authors

LSL SorianoMOM OliverSRS Redondo-Capafons

Discussion

Loading...

Member takes

Overview

Key Points

Key points are not available for this paper at this time.

Cite This Study

Soriano et al. (2024) studied this question.

synapsesocial.com/papers/68e7660bb6db6435876db9e9https://doi.org/10.1136/ejhpharm-2024-eahp.438
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 15PSQ-038 Real-world safety of ibrutinib in clinical practice in patients with chronic lymphocytic leukaemia2024
  2. 2Real-world safety and discontinuation patterns of ibrutinib in B-cell malignancies: A 9-year experience from Qatar2025
  3. 3A retrospective observational study of ibrutinib in chronic lymphocytic leukaemia in a real-life setting in France using the national claims database (OSIRIS)2024 · 1 citations
  4. 4Long‐Term Clinical Outcomes, Adherence, Persistence, and Adverse Event Management in Patients With Chronic Lymphocytic Leukemia Treated With Ibrutinib2026
  5. 5Outcomes with ibrutinib in patients with chronic lymphocytic leukaemia: Results from the German multicentre <scp>REALITY</scp> study2024 · 4 citations